Nothing Special   »   [go: up one dir, main page]

AR110381A2 - Inhibidores biarilo de tirosina cinasa de bruton - Google Patents

Inhibidores biarilo de tirosina cinasa de bruton

Info

Publication number
AR110381A2
AR110381A2 ARP170103535A ARP170103535A AR110381A2 AR 110381 A2 AR110381 A2 AR 110381A2 AR P170103535 A ARP170103535 A AR P170103535A AR P170103535 A ARP170103535 A AR P170103535A AR 110381 A2 AR110381 A2 AR 110381A2
Authority
AR
Argentina
Prior art keywords
biutyl
tirosina
cinasa
bruton
inhibitors
Prior art date
Application number
ARP170103535A
Other languages
English (en)
Original Assignee
Sunesis Pharmaceuticals Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc, Biogen Ma Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of AR110381A2 publication Critical patent/AR110381A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto, caracterizado por que es de fórmula (1); (2); o (3), o su sal farmacéuticamente aceptable.
ARP170103535A 2013-12-11 2017-12-15 Inhibidores biarilo de tirosina cinasa de bruton AR110381A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
AR110381A2 true AR110381A2 (es) 2019-03-20

Family

ID=52302344

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104620A AR098721A1 (es) 2013-12-11 2014-12-11 Inhibidores de biarilo de tirosina quinasa de bruton
ARP170103535A AR110381A2 (es) 2013-12-11 2017-12-15 Inhibidores biarilo de tirosina cinasa de bruton

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104620A AR098721A1 (es) 2013-12-11 2014-12-11 Inhibidores de biarilo de tirosina quinasa de bruton

Country Status (31)

Country Link
US (4) US9809577B2 (es)
EP (3) EP3872075A1 (es)
JP (4) JP6431914B2 (es)
KR (1) KR102413253B1 (es)
CN (3) CN109096274B (es)
AR (2) AR098721A1 (es)
AU (2) AU2014362231B2 (es)
BR (1) BR112016012860A2 (es)
CA (1) CA2932608C (es)
CL (2) CL2016001435A1 (es)
CY (1) CY1120517T1 (es)
DK (1) DK3080103T3 (es)
EA (2) EA030538B1 (es)
ES (1) ES2678021T3 (es)
HR (1) HRP20181109T1 (es)
HU (1) HUE040346T2 (es)
IL (2) IL246031B (es)
LT (1) LT3080103T (es)
MX (2) MX370103B (es)
MY (1) MY179781A (es)
NZ (1) NZ721217A (es)
PH (1) PH12016501107B1 (es)
PL (1) PL3080103T3 (es)
PT (1) PT3080103T (es)
RS (1) RS57662B1 (es)
SA (1) SA518391170B1 (es)
SG (2) SG11201604595VA (es)
SI (1) SI3080103T1 (es)
TW (3) TWI675833B (es)
WO (1) WO2015089337A1 (es)
ZA (1) ZA201706244B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711473B (zh) * 2009-09-04 2016-11-09 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
DK3080103T3 (en) 2013-12-11 2018-07-30 Biogen Ma Inc BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
EP3307731A1 (en) * 2015-06-10 2018-04-18 Biogen MA Inc. Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN109477073B (zh) * 2016-03-31 2024-04-12 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
US10710993B2 (en) 2016-06-27 2020-07-14 Hangzhou REX Pharmaceutical Co., LTD. Benzofuran pyrazole amine kinase inhibitor
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
JOP20190233A1 (ar) * 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
WO2019137985A1 (en) 2018-01-10 2019-07-18 Allinky Biopharma Tetrahydroisoquinoline compounds
FI3740481T3 (fi) 2018-01-19 2024-07-30 Cytokinetics Inc Dihydrobentsofuraani- ja indeenianalogeja sydämen sarkomeerin estäjinä
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202016097A (zh) 2018-05-14 2020-05-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶之抑制劑
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
WO2020081514A1 (en) * 2018-10-15 2020-04-23 Biogen Ma Inc. Crystalline polymorphs of bruton's tyrosine kinase inhibitors
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020232330A1 (en) 2019-05-15 2020-11-19 Biogen Ma Inc. Inhibiting agents for bruton's tyrosine kinase
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
TW202220972A (zh) 2020-08-07 2022-06-01 美商百健Ｍａ公司 Ｂｔｋ抑制劑
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
IL309528A (en) * 2021-06-21 2024-02-01 Beigene Switzerland Gmbh (R)-glutrimide CRBN ligands and methods of use
KR20240128831A (ko) * 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
WO2024146923A1 (en) 2023-01-04 2024-07-11 Ab Science Tubulin polymerization inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
CN1468225A (zh) * 2000-08-08 2004-01-14 ����-������ҩƷ��˾ 4-嘧啶胺衍生物、药用组合物和相关方法
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
BR122021011787B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
UA99899C2 (ru) * 2005-11-01 2012-10-25 Таргеджен, Инк. Биарил-мета-пиримидиновые ингибиторы киназ
BRPI0706747A2 (pt) * 2006-01-30 2011-04-05 Exelixis Inc 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EA200900616A1 (ru) * 2006-11-01 2010-04-30 Хрома Терапьютикс Лтд. Ингибиторы ikk-бета серин-треонин протеинкиназы
EP2125819B1 (en) * 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
KR101701109B1 (ko) * 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
WO2010059658A1 (en) * 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
CN102711473B (zh) * 2009-09-04 2016-11-09 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
JP5095044B1 (ja) 2011-03-31 2012-12-12 美津濃株式会社 アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ
CA2832919A1 (en) 2011-04-12 2012-10-18 Ryan C. Holcomb Compounds, compositions, and therapeutic uses thereof
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
DK3080103T3 (en) * 2013-12-11 2018-07-30 Biogen Ma Inc BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
SG11201609981RA (en) * 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Also Published As

Publication number Publication date
WO2015089337A1 (en) 2015-06-18
PH12016501107A1 (en) 2016-07-11
JP7076022B2 (ja) 2022-05-26
JP6431914B2 (ja) 2018-11-28
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
CN109096274A (zh) 2018-12-28
CN109096274B (zh) 2022-07-01
EA201792348A1 (ru) 2018-09-28
CA2932608C (en) 2023-02-14
EP3080103B1 (en) 2018-04-18
CL2016001435A1 (es) 2017-06-09
CN106459002A (zh) 2017-02-22
HUE040346T2 (hu) 2019-03-28
AU2014362231A1 (en) 2016-07-07
BR112016012860A2 (pt) 2017-08-08
AR098721A1 (es) 2016-06-08
US10759783B2 (en) 2020-09-01
SA518391170B1 (ar) 2022-08-25
US20190218204A1 (en) 2019-07-18
JP6526167B2 (ja) 2019-06-05
DK3080103T3 (en) 2018-07-30
TW201536765A (zh) 2015-10-01
EP3080103B9 (en) 2018-09-19
IL246031A0 (en) 2016-08-02
ZA201706244B (en) 2019-04-24
CN108947913A (zh) 2018-12-07
SG10201908558WA (en) 2019-10-30
CA2932608A1 (en) 2015-06-18
EP3080103A1 (en) 2016-10-19
MX370103B (es) 2019-12-02
PH12016501107B1 (en) 2016-07-11
TW201811772A (zh) 2018-04-01
JP2018035201A (ja) 2018-03-08
AU2019201997B2 (en) 2020-09-17
US9809577B2 (en) 2017-11-07
JP2016539996A (ja) 2016-12-22
IL246031B (en) 2019-10-31
US10081619B2 (en) 2018-09-25
RS57662B1 (sr) 2018-11-30
JP2019163280A (ja) 2019-09-26
MX2016007611A (es) 2016-09-09
MX2019014228A (es) 2020-01-23
US11572356B2 (en) 2023-02-07
TWI608002B (zh) 2017-12-11
CY1120517T1 (el) 2019-07-10
KR102413253B1 (ko) 2022-06-27
EP3357921A2 (en) 2018-08-08
US20180093973A1 (en) 2018-04-05
US20160311802A1 (en) 2016-10-27
EA037942B1 (ru) 2021-06-10
PT3080103T (pt) 2018-07-23
EP3872075A1 (en) 2021-09-01
US20220332705A1 (en) 2022-10-20
LT3080103T (lt) 2018-08-10
CL2017001459A1 (es) 2018-03-23
HRP20181109T1 (hr) 2018-11-02
CN106459002B (zh) 2018-08-21
IL269569B (en) 2021-03-25
PL3080103T3 (pl) 2018-10-31
MY179781A (en) 2020-11-13
AU2019201997C1 (en) 2021-03-18
TW202017931A (zh) 2020-05-16
IL269569A (en) 2019-11-28
ES2678021T3 (es) 2018-08-08
SI3080103T1 (sl) 2018-11-30
NZ721217A (en) 2021-12-24
AU2019201997A1 (en) 2019-04-18
EA201691114A1 (ru) 2016-11-30
EP3357921A3 (en) 2018-09-12
KR20160106072A (ko) 2016-09-09
EA030538B1 (ru) 2018-08-31
TWI675833B (zh) 2019-11-01
JP2021091733A (ja) 2021-06-17
AU2014362231B2 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
PE20151654A1 (es) Inhibidores de cdc7
ECSP17054980A (es) Inhibidores selectivos de bace1
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
RS54730B1 (sr) Inhibitori beta sekretaze
AR095097A1 (es) Compuestos de fenoxietoxi
AR105967A1 (es) Sales de un inhibidor de pim quinasa
EA201500931A1 (ru) Производные пиридин-4-ила
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2015013740A (es) Derivados de pirazolnaftridinona, preparacion y uso terapautico de los mismos.